| INTRODUCTION
A wide variety of workplace agents can cause the development of sensitizer-induced occupational asthma (OA) which is characterized by an asymptomatic period of exposure before the inception of work-related asthma symptoms (ie, the "latency period" necessary to acquire immunologic sensitization) and the clinical features of a specific hypersensitivity response to a workplace agent. [1] [2] [3] [4] These agents are usually categorized into high-molecular-weight (HMW) (glyco)proteins from vegetal and animal origins and low-molecularweight (LMW) chemicals (<1 kDa). 5 HMW proteins and a few LMW compounds (eg, platinum salts, reactive dyes, acid anhydrides, sulfonechloramide, and some wood species) act through a documented IgE-mediated mechanism while for most LMW, the immunologic mechanisms leading to airway sensitization remain poorly elucidated. 5 There is evidence form earlier studies that there are differences between OA caused by HMW and LMW agents in terms of clinical characteristics. [6] [7] [8] [9] A few studies investigated OA due to these two types of agents in terms of the baseline sputum inflammatory profile [10] [11] [12] or the pattern of bronchial response 13, 14 and the changes in nonspecific bronchial hyperresponsiveness (BHR) 12, 13 and markers of airway inflammation 12, 15 induced by challenge exposures. However, the clinical and inflammatory patterns associated with these two categories of agents causing OA have not yet been comprehensively described.
The aim of this study was to compare a broad range of clinical, functional, and inflammatory characteristics in a large cohort of subjects with a diagnosis of OA induced by HMW and LMW agents ascertained by a specific inhalation challenge (SIC) to determine whether these two categories of sensitizing agents are associated with distinct phenotypic profiles.
| METHODS

| Study design
This study was conducted among an international, multicenter retro- accessed December 28, 2017) . Based on these treatment steps, the level of asthma severity was categorized as "untreated" (step 0);
| Ethics
"mild" (step 1-2); "moderate" (step 3); and "severe" (step 4-5). The level of asthma control could only be characterized by the frequency of short-acting β 2 -agonist (SABA) use as most centers failed to use validated instruments for the assessment of asthma control (eg, Asthma Control Test, Asthma Control Questionnaire, or GINA symptom control tool). For the purpose of this study, "poor symptom control" was defined by the need for a SABA at least once a day as a surrogate marker of asthma control. The number of severe exacerbations requiring oral corticosteroids for at least 3 consecutive days or emergency room visit or hospitalization over the last 12 months at work was also recorded. 16, 17 In addition, we used a definition of severe asthma adapted from the European Respiratory Society/American Thoracic Society recommendations 18 that require a high-intensity treatment (GINA treatment steps 4-5) and any one of the following four criteria indicating uncontrolled asthma: (a) poor symptom control; (b) two or more severe exacerbations in the previous year; (c)
G R A P H I C A L A B S T R A C T
This large European, multicenter, retrospective cohort of subjects with occupational asthma (n = 1167) documented by a positive specific inhalation challenge highlighted clinical phenotypic differences between high-and low-molecular-weight causal agents. High-molecular-weight agents were associated with a higher likelihood of atopy, work-related rhinoconjunctivitis, baseline airflow limitation, early asthmatic reactions, and higher levels of FeNO. Occupational asthma due to low-molecular-weight agents was associated with a higher rate of chest tightness and sputum at work, a higher risk of severe asthma exacerbations, and late asthmatic reactions. Detailed information on the methodology and interpretation of SICs is available in the Data S1.
| Markers of airway inflammation
The data pertaining to markers of airway inflammation included "eosinophilic" (ie, ≥3% eosinophils and <76% neutrophils); "neutrophilic" (ie, ≥76% and <3% eosinophils); "paucigranulocytic" (ie, <3% eosinophils and <76% neutrophils); or "mixed granulocytic"
(ie, ≥76% neutrophils and ≥3% eosinophils). 20 with OA caused by HMW agents as compared to LMW agents. The independent variables incorporated into these regressions were selected based on P-value ≤0.1 in univariate comparisons after elimination of variables with >10% missing values (Data S1). Additional multivariate logistic regressions were performed to identify the variables associated with a baseline blood eosinophil count >300/μL and a postchallenge increase in FeNO > 17.5 ppb (Data S1) in subgroups of subjects for whom the data were available (blood eosinophils, n = 516; pre-and postchallenge FeNO, n = 356). Statistical analysis was performed using the R software version 3.4.1 (www.r-project.
org). A P-value <0.05 was considered significant.
3 | RESULTS
| Population
The cohort included 1180 patients with OA ascertained by a positive SIC result. The agents that induced a positive SIC response are presented in Table 1 . These agents were LMW compounds in 635 (53.8%) and HMW agents in 544 (46.1%) of the SICs, while the causal agent was not precisely identified in 13 subjects.
T A B L E 1 Causal agents
High-molecularweight agents n (%) NOS, not otherwise specified. a % of total identified agents (n = 1167); the causal agent was not precisely identified in 13 subjects.
T A B L E 2 Clinical characteristics of subjects with occupational asthma caused by high-and low-molecular-weight agents
Characteristic High-molecular-weight agents (n = 544) Low-molecular-weight agents (n = 623) P-value 
| Clinical characteristics
When compared to subjects with OA caused by LMW agents, those who demonstrated a positive response to a HMW agent were slightly younger, more often never smokers, and more frequently atopic ( Table 2) . They reported more often work-related rhinitis, conjunctivitis and wheezing at work, but less often chest tightness and sputum production.
The median duration of exposure to the causal agent before the onset of work-related asthma symptoms (ie, the "latency period") and the duration of asthma symptoms while exposed at work was slightly longer in subject with OA caused by HMW agents compared to those with OA due to LMW agents. The median (IQR) daily dose of inhaled corticosteroid (ICS) was slightly higher in subjects with OA caused by HMW agents (500 μg [0-1000]) than in those with LMW agent-induced OA (400 μg [0-1000]; P = 0.040), which seemed to be mainly related to a higher rate of subjects who were not treated with ICS in the latter group, while more subject received a low dose of ICS in the former group. Subjects with OA caused by a LMW agent reported a higher rate (26%) of severe asthma exacerbation while exposed at work as compared to subjects exposed to HMW agents (19%; P = 0.008).
| Lung function parameters
Baseline spirometry (Table 3) showed a slightly higher proportion of subjects with a FEV 1 < 80% of predicted value and airflow obstruction in subjects with OA due to HMW agents (23% and 13%, respectively) as compared to OA related to LMW agents 18%
(P = 0.020) and 10% (P = 0.080), respectively. There was no significant difference between the two groups with regard to the baseline level of BHR and the magnitude of the increase in BHR assessed 24 hours after the challenge exposure. However, BHR was slightly more often absent at baseline assessment in subjects with LMW agent-induced OA (31.7%) than in those with OA due to HMW (25.6%; P = 0.027). 
| Multivariate analysis
| Markers of airway inflammation
Peripheral blood eosinophilia >300/μL was significantly more frequent in OA due to HMW agents (49%) than in OA induced by LMW agents (34%; P < 0.001) ( There were no differences between the two groups with regard to the baseline and postchallenge sputum eosinophil and neutrophil counts. However, among subjects for whom a suitable sputum sample was available both at baseline and postchallenge assessments (n = 288), a higher proportion of subjects with OA caused by HMW agents showed a switch from the paucigranulocytic to the eosinophilic pattern (52 of 73, 71.2%) as compared to LMW agents (24 of 47;
51.1%; P = 0.025).
| DISCUSSION
This study is, to our knowledge, the first that thoroughly compared OA caused by HMW and LMW agents with respect to clinical and functional characteristics in a large cohort of subjects with a diagnosis of OA ascertained by SIC. The finding of this study is consistent with previous studies that assessed rhinitis, conjunctivitis, atopy, and the pattern of asthmatic reactions in OA due to HMW and LMW agents. 6, 9, 13, 14, 23 In addition, this study demonstrated differences in the pattern of work-related asthma symptoms, as the subjects with OA due to LMW agents showed a higher likelihood of experiencing chest tightness at work and daily sputum production. These findings may be relevant to the development of predictive models and algorithms for diagnosing OA based on simple clinical features and further indicate that these instruments should be developed separately for workers exposed to HMW and LMW agents, as already suggested by a prospective study that assessed the usefulness of questionnaire items for predicting the diagnosis of OA. 24 In this study, wheezing, and nasal and ocular itching at work were positively associated with the presence of OA in the case of HMW, but not LMW agents.
Remarkably, this study revealed a higher risk of airflow obstruction in OA caused by HMW agents, whereas OA due to LMW agents was associated with a higher rate of severe exacerbations independently from global assessments of asthma severity graded according to either the GINA treatment steps (mild, moderate, and severe) or the ERS/ATS criteria. 18 These results seem discordant from a recent monocentric study of 73 subjects with OA which reported a higher risk of moderate/severe persistent asthma (OR:
7.16 [1.13-15.20] ; P = 0.036) in subjects with OA caused by LMW agents. 9 However, in the study by Meca et al, 9 the severity of asthma was graded using a global outcome measure based on GINA guidelines 2010. As highlighted in recent years, 16, 17 the amount of medication required to achieve asthma control is a key element for assessing asthma severity (ie, the intrinsic intensity of the disease process) during treatment, while the level of asthma control is best reflected by both the magnitude of asthma-related impairment and the frequency of exacerbations. Our results further outline the importance of assessing separately the diverse components of asthma control as the rates of airflow limitation on spirometry and exacerbations were differently impacted in OA due to HMW and T A B L E 3 Functional characteristics of subjects with occupational asthma caused by high-and low-molecular-weight agents
Characteristic
High-molecularweight agents (n = 544)
Low-molecularweight agents (n = 623) P-value There is currently discordant information on the pattern of airway inflammation in OA caused by either HMW or LMW agents.
Two studies reported a lower sputum eosinophilia at baseline in OA due to LMW agents as compared to HMW agents, 10,14 although this was not confirmed in the cohort described by Prince et al. 12 In addition, the latter study failed to find differences between HMW and LMW agents in the postchallenge changes in the level of BHR and granulocyte counts as compared to baseline values. 12 In keeping with this study, 12 OA due to HMW and LMW agents did not differ in the baseline and postchallenge sputum eosinophil and neutrophil counts in our cohort. Interestingly, a high proportion of the subjects in our cohort (44.1%) demonstrated a paucigranulocytic pattern of sputum cells at baseline assessment. This paucigranulocytic pattern has been considered as a stable noninflammatory phenotype of asthma associated with a distinct outcome in terms of severe exacerbations and responsiveness to ICS. 27 ,28 However, we observed that a high proportion of our subjects with paucigranulocytic asthma at baseline (76/120, 63.3%) shifted toward an eosinophilic pattern after challenge exposure to the causal agent. Of note, HMW agents induced more frequently a switch from "paucigranulocytic asthma" to "eosinophilic asthma" than LMW agents. Our finding may provide novel insight into the understanding of paucigranulocytic asthma by indicating that it may be a transient phenotype which can be rapidly affected by environmental exposures, such as occupational sensitizing agents and perhaps nonoccupational allergens. In addition, these findings further support the study of Lemière et al 29 who suggested that the changes in the type of airway inflammation induced by exposure to an occupational agent may be more important than the baseline inflammatory profile to predict the outcome of OA. These investigators found that a noneosinophilic response (ie, a postchallenge increase in sputum eosinophils <2%) was associated with worse asthma control and a greater decline in FEV 1 at follow-up assessment.
There is considerable interest in the noninvasive assessment of eosinophilic airway inflammation through the measurement of FeNO and blood eosinophils in the diagnosis and management of asthma. 30, 31 In our cohort, asthmatic reactions induced by HMW agents were more frequently associated with a postchallenge increase in FeNO compared to LMW agents, corroborating a recent report by
Lemière et al. 15 We also found that OA caused by HMW agents 
The figure illustrates the main results of the multivariate logistic regression analysis for the clinical and functional characteristics that are associated with occupational asthma caused by high-molecular-weight agents as the outcome (odds ratio > 1) and low-molecularweight agents as the reference (odds ratio < 1). Work-related rhinitis and conjunctivitis were physician-based diagnoses. Airway obstruction was defined by a FEV 1 < 80% predicted value and a FEV 1 /FVC ratio <70%. The presence of atopy was documented by at least one positive skin-prick test response to a battery of locally relevant inhalant allergens. Asthma exacerbations were defined by the need for oral corticosteroids for at least 3 consecutive days or emergency room visit or hospitalization during the last 12 mo at work 16 exhibited more frequently a baseline peripheral blood eosinophilia as compared to LMW agents, although the two groups were similar with regard to the baseline sputum eosinophil counts. Currently, only one study has evaluated the usefulness of measuring blood eosinophils in OA. 32 These investigators reported that a blood eosinophil count >300/μL was unable to differentiate subjects with positive and negative SICs and that postchallenge changes in blood and sputum eosinophil counts did not correlate, although they failed to provide separate information for HMW and LMW agents. Overall, our findings further highlight an important degree of discordance between sputum eosinophilia and TH2-related biomarkers, indicating that these indices are likely to reflect different pathophysiological pathways.
30,31,33,34
T A B L E 4 Airway inflammation markers in subjects with occupational asthma caused by high-and low-molecular-weight agents
Characteristic
High-molecular-weight agents (n = 544)
Low-molecular-weight agents (n = 623) P-value Two systematic reviews of follow-up studies in subjects with OA provided some evidence that subjects with OA related to HMW agents are more likely to have persistent BHR after complete avoidance of exposure to the causal agent. 36, 38 In conclusion, this study highlighted phenotypic differences between OA caused by HMW and LMW agents in their clinical and functional characteristics, and inflammatory biomarkers profiles.
Whether specific pathobiologic pathways are involved in these OA subphenotypes need to be addressed in future studies. From a clinical perspective, further investigation is required to evaluate the impact of the observed phenotypic differences between HMW and LMW agents on the outcome of OA. Ultimately, these studies would help to determine whether the identification of phenotypic characteristics associated with a higher risk for a worse outcome might contribute to a more personalized management approach.
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